首页 > 最新文献

Practical Radiation Oncology最新文献

英文 中文
Radiation Therapy for Rectal Cancer: An ASTRO Clinical Practice Guideline Focused Update. 直肠癌放射治疗:ASTRO临床实践指南重点更新。
IF 3.4 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-16 DOI: 10.1016/j.prro.2024.11.003
Jennifer Y Wo, Jonathan B Ashman, Nishin A Bhadkamkar, Lisa Bradfield, Daniel T Chang, Nader Hanna, Maria Hawkins, Michael Holtz, Edward Kim, Patrick Kelly, Diane C Ling, Jeffrey R Olsen, Manisha Palta, Ann C Raldow, Erika Ruiz-Garcia, Arshin Sheybani, Karyn B Stitzenberg, Prajnan Das

Purpose: With the results of several recently published clinical trials, this guideline focused update provides evidence-based recommendations for the indications and dose-fractionation regimens for neoadjuvant radiation therapy (RT), optimal sequencing of RT and systemic therapy in the context of total neoadjuvant therapy (TNT), and considerations for selective omission of RT and surgery for rectal cancer.

Methods: The American Society for Radiation Oncology convened a multidisciplinary task force to update 3 key questions that focused on the role of RT for patients with operable rectal cancer. The key questions addressed (1) indications for neoadjuvant RT, (2) selection of neoadjuvant regimens, and (3) indications for consideration of a nonoperative management (NOM) or local excision approach after definitive/preoperative chemoradiation. Recommendations were based on a systematic literature review and created using a predefined consensus-building methodology and system for quality of evidence grading and strength of recommendation.

Results: For patients with stage II-III rectal cancer, neoadjuvant RT was strongly recommended; however, among patients deemed at lower risk of locoregional recurrence, consideration of omission of neoadjuvant RT was conditionally recommended in favor of neoadjuvant chemotherapy with a favorable treatment response or upfront surgery. For patients with T3-T4 and node positive rectal cancer undergoing neoadjuvant RT, a TNT approach was strongly recommended. Among patients with higher risk of locoregional recurrence, TNT with chemotherapy before or after long-course chemoradiation was strongly recommended, whereas TNT with short-course RT followed by chemotherapy was conditionally recommended. For patients with rectal cancer for whom NOM is a priority, concurrent chemoradiation followed by consolidation chemotherapy was strongly recommended. Selection of RT dose-fractionation regimen, sequencing of therapies, and consideration of NOM should be determined by multidisciplinary consensus, and based on disease extent, disease location, patient preferences, and quality of life considerations.

Conclusions: The task force has proposed recommendations to inform best clinical practices on the use of RT for rectal cancer with strong emphasis on multidisciplinary care. Future studies should focus on further addressing optimal treatment regimens to allow for more personalized recommendations based on individual risk stratification and patient priorities regarding quality of life.

目的:根据最近公布的几项临床试验结果,本指南重点更新了新辅助放疗(RT)的适应症和剂量-分次方案、新辅助放疗和全身治疗(TNT)的最佳排序,以及选择性放弃RT和直肠癌手术的注意事项等方面的循证建议:美国放射肿瘤学会召集了一个多学科工作组,以更新 3 个关键问题,重点关注 RT 在可手术直肠癌患者中的作用。这些关键问题涉及:(1) 新辅助 RT 的适应症;(2) 新辅助治疗方案的选择;(3) 明确/术前化疗后考虑非手术治疗 (NOM) 或局部切除方法的适应症。推荐意见以系统性文献综述为基础,并采用预先确定的建立共识方法和证据质量分级及推荐强度系统:结果:对于II-III期直肠癌患者,强烈建议进行新辅助RT治疗;然而,对于被认为局部复发风险较低的患者,有条件地建议考虑省略新辅助RT治疗,转而采用治疗反应良好的新辅助化疗或先期手术治疗。对于接受新辅助 RT 的 T3-T4 和结节阳性直肠癌患者,强烈建议采用 TNT 方法。在局部复发风险较高的患者中,强烈推荐在长程化疗之前或之后采用 TNT 加化疗的方法,而有条件地推荐采用 TNT 加短程 RT 再加化疗的方法。对于以 NOM 为优先选择的直肠癌患者,强烈建议同时进行化疗后再进行巩固化疗。RT剂量-分次方案的选择、疗法的排序以及对NOM的考虑应通过多学科共识来确定,并以疾病程度、疾病位置、患者偏好以及生活质量考虑为基础:特别工作组提出了一些建议,为使用 RT 治疗直肠癌的最佳临床实践提供依据,并着重强调了多学科护理。未来的研究应侧重于进一步探讨最佳治疗方案,以便根据个体风险分层和患者对生活质量的优先考虑提供更个性化的建议。
{"title":"Radiation Therapy for Rectal Cancer: An ASTRO Clinical Practice Guideline Focused Update.","authors":"Jennifer Y Wo, Jonathan B Ashman, Nishin A Bhadkamkar, Lisa Bradfield, Daniel T Chang, Nader Hanna, Maria Hawkins, Michael Holtz, Edward Kim, Patrick Kelly, Diane C Ling, Jeffrey R Olsen, Manisha Palta, Ann C Raldow, Erika Ruiz-Garcia, Arshin Sheybani, Karyn B Stitzenberg, Prajnan Das","doi":"10.1016/j.prro.2024.11.003","DOIUrl":"https://doi.org/10.1016/j.prro.2024.11.003","url":null,"abstract":"<p><strong>Purpose: </strong>With the results of several recently published clinical trials, this guideline focused update provides evidence-based recommendations for the indications and dose-fractionation regimens for neoadjuvant radiation therapy (RT), optimal sequencing of RT and systemic therapy in the context of total neoadjuvant therapy (TNT), and considerations for selective omission of RT and surgery for rectal cancer.</p><p><strong>Methods: </strong>The American Society for Radiation Oncology convened a multidisciplinary task force to update 3 key questions that focused on the role of RT for patients with operable rectal cancer. The key questions addressed (1) indications for neoadjuvant RT, (2) selection of neoadjuvant regimens, and (3) indications for consideration of a nonoperative management (NOM) or local excision approach after definitive/preoperative chemoradiation. Recommendations were based on a systematic literature review and created using a predefined consensus-building methodology and system for quality of evidence grading and strength of recommendation.</p><p><strong>Results: </strong>For patients with stage II-III rectal cancer, neoadjuvant RT was strongly recommended; however, among patients deemed at lower risk of locoregional recurrence, consideration of omission of neoadjuvant RT was conditionally recommended in favor of neoadjuvant chemotherapy with a favorable treatment response or upfront surgery. For patients with T3-T4 and node positive rectal cancer undergoing neoadjuvant RT, a TNT approach was strongly recommended. Among patients with higher risk of locoregional recurrence, TNT with chemotherapy before or after long-course chemoradiation was strongly recommended, whereas TNT with short-course RT followed by chemotherapy was conditionally recommended. For patients with rectal cancer for whom NOM is a priority, concurrent chemoradiation followed by consolidation chemotherapy was strongly recommended. Selection of RT dose-fractionation regimen, sequencing of therapies, and consideration of NOM should be determined by multidisciplinary consensus, and based on disease extent, disease location, patient preferences, and quality of life considerations.</p><p><strong>Conclusions: </strong>The task force has proposed recommendations to inform best clinical practices on the use of RT for rectal cancer with strong emphasis on multidisciplinary care. Future studies should focus on further addressing optimal treatment regimens to allow for more personalized recommendations based on individual risk stratification and patient priorities regarding quality of life.</p>","PeriodicalId":54245,"journal":{"name":"Practical Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142741178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Financial Toxicity and Quality-of-Life Outcomes on a Phase 1 5-fraction Stereotactic Partial Breast Irradiation Protocol for Early-Stage Breast Cancer. 针对早期乳腺癌的第一阶段 5 分次立体定向部分乳腺放射治疗方案的经济毒性和生活质量结果。
IF 3.4 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-16 DOI: 10.1016/j.prro.2024.08.012
Ambrosia Simmons, David Sher, Dr Dong Wook Nathan Kim, Marilyn Leitch, Rachel Wooldridge, Sally Goudreau, Stephen Seiler, Sarah Neufeld, Maggie Stein, Kevin Albuquerque, Ann Spangler, John Heinzerling, Dan Garwood, Stella Stevenson, Chul Ahn, Chuxiong Ding, Robert D Timmerman, Asal Rahimi

Purpose: We report the financial toxicity and quality-of-life outcomes of our prospective phase 1 dose-escalation study of 5-fraction stereotactic partial breast irradiation (S-PBI) for early-stage breast cancer.

Materials and methods: Women with unifocal in situ or invasive epithelial histologies, clinical stages 0, I, or II with tumor size < 3 cm treated with lumpectomy were enrolled in our phase 1 5-fraction S-PBI dose-escalation trial. Our institutionally generated questionnaire on the "Patient Perspective Cost and Convenience of Care" and the EuroQol 5-Dimension 5-level questionnaire were administered to patients treated at follow-up.

Results: Between 2010 and 2015, 68 of the 75 patients who enrolled and completed treatment on trial completed at least some component of either the EuroQol 5-Dimension 5-level questionnaire or the "Patient Perspective Cost and Convenience of Care" questionnaire. Nearly all patients reported very high satisfaction with their treatment overall, particularly the shortened length of treatment. Over half of the patients reported some level of financial toxicity (FT) despite a significantly shortened treatment time. Patients who reported any FT were significantly younger than patients with no financial burden of treatment (means 59.2 and 63.7, respectively, P = .03). There was no difference in those who reported any level of FT based on patient race, ethnicity, marital, or employment status. This S-PBI regimen did not significantly affect quality of life over a 4-year follow-up.

Conclusions: These patient-reported outcomes suggest that the use of accelerated partial breast irradiation may offer low FT rates in breast cancer care, particularly for disadvantaged patient groups.

目的:我们报告了针对早期乳腺癌的 5 分次立体定向乳腺部分照射(S-PBI)前瞻性 1 期剂量递增研究的经济毒性和生活质量结果:单灶原位或浸润性上皮组织学,临床分期为0、I或II期,肿瘤大小小于3厘米,接受过肿块切除术治疗的女性参加了我们的1期5分次S-PBI剂量递增试验。在随访时,我们对接受治疗的患者进行了由本院编制的 "患者视角下的医疗成本和便利性 "问卷调查和EuroQol 5维度5级问卷调查:2010年至2015年期间,在75名参加试验并完成治疗的患者中,有68人至少完成了EuroQol 5维5级问卷或 "患者眼中的医疗成本和便利性 "问卷的部分内容。几乎所有患者都表示对治疗的总体满意度非常高,尤其是缩短了治疗时间。尽管治疗时间大大缩短,但仍有一半以上的患者表示存在一定程度的经济毒性(FT)。报告有经济负担的患者明显比没有治疗经济负担的患者年轻(平均值分别为 59.2 和 63.7,P = .03)。报告有任何经济负担的患者在种族、民族、婚姻或就业状况方面没有差异。在为期4年的随访中,这种S-PBI疗法对生活质量没有明显影响:这些患者报告的结果表明,在乳腺癌治疗中使用加速乳腺部分照射可能会降低FT率,尤其是对弱势患者群体而言。
{"title":"Financial Toxicity and Quality-of-Life Outcomes on a Phase 1 5-fraction Stereotactic Partial Breast Irradiation Protocol for Early-Stage Breast Cancer.","authors":"Ambrosia Simmons, David Sher, Dr Dong Wook Nathan Kim, Marilyn Leitch, Rachel Wooldridge, Sally Goudreau, Stephen Seiler, Sarah Neufeld, Maggie Stein, Kevin Albuquerque, Ann Spangler, John Heinzerling, Dan Garwood, Stella Stevenson, Chul Ahn, Chuxiong Ding, Robert D Timmerman, Asal Rahimi","doi":"10.1016/j.prro.2024.08.012","DOIUrl":"10.1016/j.prro.2024.08.012","url":null,"abstract":"<p><strong>Purpose: </strong>We report the financial toxicity and quality-of-life outcomes of our prospective phase 1 dose-escalation study of 5-fraction stereotactic partial breast irradiation (S-PBI) for early-stage breast cancer.</p><p><strong>Materials and methods: </strong>Women with unifocal in situ or invasive epithelial histologies, clinical stages 0, I, or II with tumor size < 3 cm treated with lumpectomy were enrolled in our phase 1 5-fraction S-PBI dose-escalation trial. Our institutionally generated questionnaire on the \"Patient Perspective Cost and Convenience of Care\" and the EuroQol 5-Dimension 5-level questionnaire were administered to patients treated at follow-up.</p><p><strong>Results: </strong>Between 2010 and 2015, 68 of the 75 patients who enrolled and completed treatment on trial completed at least some component of either the EuroQol 5-Dimension 5-level questionnaire or the \"Patient Perspective Cost and Convenience of Care\" questionnaire. Nearly all patients reported very high satisfaction with their treatment overall, particularly the shortened length of treatment. Over half of the patients reported some level of financial toxicity (FT) despite a significantly shortened treatment time. Patients who reported any FT were significantly younger than patients with no financial burden of treatment (means 59.2 and 63.7, respectively, P = .03). There was no difference in those who reported any level of FT based on patient race, ethnicity, marital, or employment status. This S-PBI regimen did not significantly affect quality of life over a 4-year follow-up.</p><p><strong>Conclusions: </strong>These patient-reported outcomes suggest that the use of accelerated partial breast irradiation may offer low FT rates in breast cancer care, particularly for disadvantaged patient groups.</p>","PeriodicalId":54245,"journal":{"name":"Practical Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142649685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Time to Slash SABR From Our Lexicon. 是时候把 SABR 从我们的词典中删掉了。
IF 3.4 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-13 DOI: 10.1016/j.prro.2024.10.015
Paul E Wallner, Michael L Steinberg
{"title":"Time to Slash SABR From Our Lexicon.","authors":"Paul E Wallner, Michael L Steinberg","doi":"10.1016/j.prro.2024.10.015","DOIUrl":"https://doi.org/10.1016/j.prro.2024.10.015","url":null,"abstract":"","PeriodicalId":54245,"journal":{"name":"Practical Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142640431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Consensus Guidelines for Delineation of Clinical Target Volumes for Intensity-Modulated Radiotherapy for Intact Cervical Cancer: An Update. 宫颈癌调强放射治疗临床靶区划分共识指南》:更新版。
IF 3.4 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-13 DOI: 10.1016/j.prro.2024.11.004
Emma C Fields, Walter R Bosch, Kevin V Albuquerque, Rohini Bhatia, Junzo Chino, Brandon Dyer, Beth Erickson, Denise Fabian, David Gaffney, Scott Glaser, Kathy Han, Lara Hathout, I-Chow Hsu, Naresh Jegadeesh, Jenna Kahn, Elizabeth Kidd, Ann Klopp, Eric Leung, Lilie Lin, Michelle Ludwig, Tianjun Ma, Loren Mell, Jyoti Mayadev, Ivy Petersen, Lorraine Portelance, Dominique Rash, Neil Taunk, Akila Viswanathan, Aaron Wolfson, Catheryn Yashar, Anamaria Yeung, Emi Yoshida, Christine M Fisher

Purpose: Accurate target delineation is essential when using intensity-modulated radiotherapy (IMRT) for intact cervical cancer. In 2011, the Radiation Therapy Oncology Group (RTOG) published a consensus guideline using magnetic resonance imaging (MRI). The current project expands on the previous atlas by including computed tomography (CT)-based contours, contours with MRI and positron- emission- tomography (PET) registrations, the addition of common and complex scenarios, and to incorporate information on simulation and treatment planning techniques.

Methods and materials: Twenty-eight experts in gynecologic radiation oncology contoured three cases, first on a non-contrast CT simulation scan, then with registered diagnostic scans. The cases included (1) FIGO IIIC1 with a bulky tumor and vaginal metastasis, (2) FIGO IIB with calcified uterine fibromas, and (3) FIGO IIIC2 with large lymph nodes. The contours on all six datasets (three CT simulations without diagnostic images and three with registered images) were analyzed for consistency of delineation using an expectation-maximization algorithm for simultaneous truth and performance level estimation (STAPLE) with kappa statistics as a measure of agreement. The contours were reviewed, discussed, and edited in a group meeting prior to finalizing.

Results: Contours showed considerable agreement between experts in each of the cases with kappa statistics of 0.67-0.72. For each case, diagnostic PET±MRI was associated with an increase in volume. The largest increase was the CTV primary for Case 2 with a 20% increase in volume and 54% increase in STAPLE estimate volume, which may be due to variance in registration priorities. For the third case, 92.9% increased their CTVs based on the addition of the diagnostic PET scan. The main areas of variance were in determining the superior extent of CTV coverage, coverage of the mesorectum, and simulation and planning protocols.

Conclusions: This study shows the value as well as the challenges of using co-registered diagnostic imaging, with an average increase in volumes when incorporating MRI and PET.

目的:在使用调强放射治疗(IMRT)治疗完整的宫颈癌时,准确的靶区划分至关重要。2011 年,放射治疗肿瘤学组 (RTOG) 发布了一份使用磁共振成像 (MRI) 的共识指南。目前的项目在之前地图集的基础上进行了扩展,包括基于计算机断层扫描(CT)的轮廓图、磁共振成像和正电子发射断层扫描(PET)登记的轮廓图,增加了常见和复杂的情况,并纳入了模拟和治疗计划技术的信息:28 位妇科放射肿瘤学专家对三个病例进行了轮廓分析,首先是非对比 CT 模拟扫描,然后是注册诊断扫描。病例包括:(1) FIGO IIIC1,肿瘤巨大且有阴道转移;(2) FIGO IIB,子宫纤维瘤钙化;(3) FIGO IIIC2,淋巴结较大。对所有六个数据集(三个不带诊断图像的 CT 模拟和三个带注册图像的数据集)上的轮廓进行了分析,采用期望最大化算法进行同步真相和性能水平估计 (STAPLE),以卡帕统计作为衡量一致性的标准。在最终确定轮廓之前,小组会议对轮廓进行了审查、讨论和编辑:结果:在每个病例中,专家之间的等值线显示出相当大的一致性,kappa 统计量为 0.67-0.72。在每个病例中,诊断性 PET±MRI 都与体积的增加有关。增加最多的是病例 2 的 CTV 基底,体积增加了 20%,STAPLE 估计体积增加了 54%,这可能是由于登记优先级的差异造成的。对于第三个病例,92.9%的人在增加诊断性 PET 扫描的基础上增加了 CTV。存在差异的主要方面是确定CTV覆盖的优势范围、直肠中叶的覆盖范围以及模拟和规划方案:这项研究显示了使用联合注册诊断成像的价值和挑战,当结合 MRI 和 PET 时,平均体积会增加。
{"title":"Consensus Guidelines for Delineation of Clinical Target Volumes for Intensity-Modulated Radiotherapy for Intact Cervical Cancer: An Update.","authors":"Emma C Fields, Walter R Bosch, Kevin V Albuquerque, Rohini Bhatia, Junzo Chino, Brandon Dyer, Beth Erickson, Denise Fabian, David Gaffney, Scott Glaser, Kathy Han, Lara Hathout, I-Chow Hsu, Naresh Jegadeesh, Jenna Kahn, Elizabeth Kidd, Ann Klopp, Eric Leung, Lilie Lin, Michelle Ludwig, Tianjun Ma, Loren Mell, Jyoti Mayadev, Ivy Petersen, Lorraine Portelance, Dominique Rash, Neil Taunk, Akila Viswanathan, Aaron Wolfson, Catheryn Yashar, Anamaria Yeung, Emi Yoshida, Christine M Fisher","doi":"10.1016/j.prro.2024.11.004","DOIUrl":"10.1016/j.prro.2024.11.004","url":null,"abstract":"<p><strong>Purpose: </strong>Accurate target delineation is essential when using intensity-modulated radiotherapy (IMRT) for intact cervical cancer. In 2011, the Radiation Therapy Oncology Group (RTOG) published a consensus guideline using magnetic resonance imaging (MRI). The current project expands on the previous atlas by including computed tomography (CT)-based contours, contours with MRI and positron- emission- tomography (PET) registrations, the addition of common and complex scenarios, and to incorporate information on simulation and treatment planning techniques.</p><p><strong>Methods and materials: </strong>Twenty-eight experts in gynecologic radiation oncology contoured three cases, first on a non-contrast CT simulation scan, then with registered diagnostic scans. The cases included (1) FIGO IIIC1 with a bulky tumor and vaginal metastasis, (2) FIGO IIB with calcified uterine fibromas, and (3) FIGO IIIC2 with large lymph nodes. The contours on all six datasets (three CT simulations without diagnostic images and three with registered images) were analyzed for consistency of delineation using an expectation-maximization algorithm for simultaneous truth and performance level estimation (STAPLE) with kappa statistics as a measure of agreement. The contours were reviewed, discussed, and edited in a group meeting prior to finalizing.</p><p><strong>Results: </strong>Contours showed considerable agreement between experts in each of the cases with kappa statistics of 0.67-0.72. For each case, diagnostic PET±MRI was associated with an increase in volume. The largest increase was the CTV primary for Case 2 with a 20% increase in volume and 54% increase in STAPLE estimate volume, which may be due to variance in registration priorities. For the third case, 92.9% increased their CTVs based on the addition of the diagnostic PET scan. The main areas of variance were in determining the superior extent of CTV coverage, coverage of the mesorectum, and simulation and planning protocols.</p><p><strong>Conclusions: </strong>This study shows the value as well as the challenges of using co-registered diagnostic imaging, with an average increase in volumes when incorporating MRI and PET.</p>","PeriodicalId":54245,"journal":{"name":"Practical Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142640430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Best practice guidelines for use of reference points in radiation oncology information systems to aggregate longitudinal dosimetric data. 在放射肿瘤信息系统中使用参考点汇总纵向剂量数据的最佳实践指南。
IF 3.4 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-12 DOI: 10.1016/j.prro.2024.09.016
Alon Witztum, Younes Jourani, Emily Y Hirata, Todd McNutt, Thomas G Purdie, Kristy K Brock, David S Hong, Michelle E Howard, Andra V Krauze, Peter A Balter, Abigail L Stockham, Elizabeth Covington, Ying Xiao, Richard Popple, Charles S Mayo

Purpose/objectives: Tracking patient dose in radiation oncology is challenging due to disparate electronic systems from various vendors. Treatment planning systems (TPS), radiation oncology information systems (ROIS), and electronic health records (EHR) lack uniformity, complicating dose tracking and reporting. To address this, we examined practices in multiple radiation oncology settings and proposed guidelines for current systems.

Material/methods: A survey was conducted among members of various professional groups to understand dose reporting practices in TPS, ROIS, and EHR systems. The aim was to identify consistent components and develop guidelines.

Results: We identified six treatment scenarios where current ROIS defaults fail in accurately representing dose totals. A standardized approach involving three reference point types - Primary Treatment Plan Reference, Dose Check, and Prescription Tracking - was proposed to address these scenarios. Standardizing naming conventions for reference points was also recommended for easier integration with EHRs. The approach requires minimal modifications to existing systems and facilitates easier data transfer and display in EHRs.

Conclusion: Standardizing reference points in commercial TPS and ROIS can bridge infrastructure gaps and improve dose tracking in complex clinical scenarios. This standardization, aligned with AAPM's TG-263, paves the way for continual development of automated, standardized, interoperable tools, enhancing the ease of sharing reference point information.

目的/目标:由于来自不同供应商的电子系统各不相同,在放射肿瘤学中跟踪患者剂量具有挑战性。治疗计划系统(TPS)、放射肿瘤信息系统(ROIS)和电子健康记录(EHR)缺乏统一性,使剂量跟踪和报告变得复杂。为了解决这个问题,我们研究了多个放射肿瘤学机构的做法,并提出了当前系统的指导原则:我们对不同专业团体的成员进行了调查,以了解 TPS、ROIS 和 EHR 系统中的剂量报告实践。目的是确定一致的组成部分并制定指南:结果:我们确定了六种治疗方案,在这些方案中,目前的 ROIS 默认值无法准确表示剂量总量。为了解决这些问题,我们提出了一种涉及三种参考点类型(主要治疗计划参考、剂量检查和处方跟踪)的标准化方法。此外,还建议对参考点进行标准化命名,以便于与电子病历集成。这种方法只需对现有系统进行最低限度的修改,并能更方便地在电子病历中传输和显示数据:结论:商业 TPS 和 ROIS 中参考点的标准化可以弥补基础设施的不足,改善复杂临床情况下的剂量跟踪。这种标准化与 AAPM 的 TG-263 保持一致,为持续开发自动化、标准化、可互操作的工具铺平了道路,从而提高了共享参考点信息的便利性。
{"title":"Best practice guidelines for use of reference points in radiation oncology information systems to aggregate longitudinal dosimetric data.","authors":"Alon Witztum, Younes Jourani, Emily Y Hirata, Todd McNutt, Thomas G Purdie, Kristy K Brock, David S Hong, Michelle E Howard, Andra V Krauze, Peter A Balter, Abigail L Stockham, Elizabeth Covington, Ying Xiao, Richard Popple, Charles S Mayo","doi":"10.1016/j.prro.2024.09.016","DOIUrl":"10.1016/j.prro.2024.09.016","url":null,"abstract":"<p><strong>Purpose/objectives: </strong>Tracking patient dose in radiation oncology is challenging due to disparate electronic systems from various vendors. Treatment planning systems (TPS), radiation oncology information systems (ROIS), and electronic health records (EHR) lack uniformity, complicating dose tracking and reporting. To address this, we examined practices in multiple radiation oncology settings and proposed guidelines for current systems.</p><p><strong>Material/methods: </strong>A survey was conducted among members of various professional groups to understand dose reporting practices in TPS, ROIS, and EHR systems. The aim was to identify consistent components and develop guidelines.</p><p><strong>Results: </strong>We identified six treatment scenarios where current ROIS defaults fail in accurately representing dose totals. A standardized approach involving three reference point types - Primary Treatment Plan Reference, Dose Check, and Prescription Tracking - was proposed to address these scenarios. Standardizing naming conventions for reference points was also recommended for easier integration with EHRs. The approach requires minimal modifications to existing systems and facilitates easier data transfer and display in EHRs.</p><p><strong>Conclusion: </strong>Standardizing reference points in commercial TPS and ROIS can bridge infrastructure gaps and improve dose tracking in complex clinical scenarios. This standardization, aligned with AAPM's TG-263, paves the way for continual development of automated, standardized, interoperable tools, enhancing the ease of sharing reference point information.</p>","PeriodicalId":54245,"journal":{"name":"Practical Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142632521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiation Therapy for Heterotopic Ossification: A Systematic Review. 异位骨化的放射治疗:系统回顾
IF 3.4 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-11 DOI: 10.1016/j.prro.2024.10.013
Christine Bang, Eric Jutkowitz, Eduardo Caputo, Sherry X Yan, Htun Ja Mai, Ghid Kanaan, Tayler Leonard, Taylor Rickard, Thomas Trikalinos, James L Rudolph, Katherine Rieke

Introduction: Heterotopic Ossification (HO) is a benign disorder characterized by ectopic bone formation in soft tissues that can lead to functional loss in patients. We conducted a systematic review of the evidence on the use of Radiation Therapy (RT) for the prevention or treatment of HO.

Methods and materials: Literature searches were conducted using Medline (via PubMed), Embase, and ClinicalTrials.gov to April 1, 2023. Medical Subject Headings (MeSH) and free text terms relevant to HO and radiation therapy were used. In brief, eligible study participants were ≥18 years of age with heterotopic ossification and were treated with low-dose, external RT. Two reviewers selected relevant abstracts and abstracted full text data for analysis. The review followed the PRISMA guidelines.

Results: Ten studies evaluating the effect of RT for either the prevention or treatment of heterotopic ossification met the inclusion for evidence synthesis. Nine RCTs did not clearly report their methods and had medium risk of bias. The studies were conducted between 1988 and 2008 with follow-up ranging on average from three to 59 months post treatment. A total of 1530 participants were analyzed, and 566 were treated with RT following fracture fixation, total hip arthroplasty (THA), or total hip replacement (THR). In pooled data from eight RCTs, there was a non-significant but clinically meaningful reduction in the presence of heterotopic ossification at follow-up for patients who received RT vs. comparators (pooled OR = 0.47, 95% CI [0.19, 1.17]. There was minimal evidence of adverse events.

Conclusion: This systematic review found a clinically, but not statistically, significant benefit of prophylactic RT for HO at follow up. These findings are tempered by a moderate risk of bias. While practice patterns vary, RT for HO prophylaxis, in high-risk patients, may have benefits that outweigh the risks.

导言:异位骨化(HO)是一种良性疾病,其特点是软组织中的异位骨形成,可导致患者功能丧失。我们对使用放射治疗(RT)预防或治疗异位骨化的证据进行了系统性回顾:我们使用 Medline(通过 PubMed)、Embase 和 ClinicalTrials.gov 对截至 2023 年 4 月 1 日的文献进行了检索。使用了与 HO 和放射治疗相关的医学主题词(MeSH)和自由文本词。简而言之,符合条件的研究参与者年龄≥18岁,患有异位骨化并接受过低剂量体外 RT 治疗。两名审稿人选择了相关摘要并摘录了全文数据进行分析。综述遵循 PRISMA 指南:10项评估RT预防或治疗异位骨化效果的研究符合证据综合的要求。9项RCT研究未明确报告其研究方法,存在中等偏倚风险。这些研究在1988年至2008年间进行,平均随访时间从治疗后3个月到59个月不等。共分析了 1530 名参与者,其中 566 人在骨折固定、全髋关节置换术(THA)或全髋关节置换术(THR)后接受了 RT 治疗。汇总八项研究的数据后发现,接受RT治疗的患者在随访时出现异位骨化的几率比接受RT治疗的患者低(汇总OR = 0.47,95% CI [0.19,1.17]),虽然不显著,但却具有临床意义。不良事件的证据极少:本系统综述发现,预防性 RT 对随访的 HO 有临床显著疗效,但无统计学意义。这些研究结果存在一定的偏倚风险。虽然实践模式各不相同,但在高风险患者中预防性 RT 治疗 HO 的益处可能大于风险。
{"title":"Radiation Therapy for Heterotopic Ossification: A Systematic Review.","authors":"Christine Bang, Eric Jutkowitz, Eduardo Caputo, Sherry X Yan, Htun Ja Mai, Ghid Kanaan, Tayler Leonard, Taylor Rickard, Thomas Trikalinos, James L Rudolph, Katherine Rieke","doi":"10.1016/j.prro.2024.10.013","DOIUrl":"https://doi.org/10.1016/j.prro.2024.10.013","url":null,"abstract":"<p><strong>Introduction: </strong>Heterotopic Ossification (HO) is a benign disorder characterized by ectopic bone formation in soft tissues that can lead to functional loss in patients. We conducted a systematic review of the evidence on the use of Radiation Therapy (RT) for the prevention or treatment of HO.</p><p><strong>Methods and materials: </strong>Literature searches were conducted using Medline (via PubMed), Embase, and ClinicalTrials.gov to April 1<sub>,</sub> 2023. Medical Subject Headings (MeSH) and free text terms relevant to HO and radiation therapy were used. In brief, eligible study participants were ≥18 years of age with heterotopic ossification and were treated with low-dose, external RT. Two reviewers selected relevant abstracts and abstracted full text data for analysis. The review followed the PRISMA guidelines.</p><p><strong>Results: </strong>Ten studies evaluating the effect of RT for either the prevention or treatment of heterotopic ossification met the inclusion for evidence synthesis. Nine RCTs did not clearly report their methods and had medium risk of bias. The studies were conducted between 1988 and 2008 with follow-up ranging on average from three to 59 months post treatment. A total of 1530 participants were analyzed, and 566 were treated with RT following fracture fixation, total hip arthroplasty (THA), or total hip replacement (THR). In pooled data from eight RCTs, there was a non-significant but clinically meaningful reduction in the presence of heterotopic ossification at follow-up for patients who received RT vs. comparators (pooled OR = 0.47, 95% CI [0.19, 1.17]. There was minimal evidence of adverse events.</p><p><strong>Conclusion: </strong>This systematic review found a clinically, but not statistically, significant benefit of prophylactic RT for HO at follow up. These findings are tempered by a moderate risk of bias. While practice patterns vary, RT for HO prophylaxis, in high-risk patients, may have benefits that outweigh the risks.</p>","PeriodicalId":54245,"journal":{"name":"Practical Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142632541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of Dry Mouth Toxicity Following 177Lu-PSMA-617 Radioligand Therapy. 177Lu-PSMA-617放射性配体治疗后的口干毒性处理。
IF 3.4 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-09 DOI: 10.1016/j.prro.2024.10.014
Abigail Pepin, Ana Kiess, J Nicholas Lukens, Philipose Mulugeta, Neil K Taunk

Treatment options for patients with metastatic castration-resistant prostate cancer include the use of radioligand therapy with 177Lu-PSMA-617. Although 177Lu-PSMA-617 can selectively target prostate cancer cells, salivary glands express PSMA on the apical lumen of the acinar epithelium. Xerostomia resulting from the use of radioligand therapy is common. Herein, we report on a case of a Common Terminology Criteria for Adverse Events version 5 grade 2 dry mouth event after administration of 177Lu-PSMA-617. The patient was managed with oral hygiene and xerostomia mitigation strategies using oral rinses.

转移性耐受性前列腺癌患者的治疗方案包括使用 177Lu-PSMA-617 放射配体疗法。虽然 177Lu-PSMA-617 可用于选择性地靶向前列腺癌细胞,但唾液腺在尖状上皮的顶端管腔中表达 PSMA。使用放射性配体治疗导致的口腔干燥症很常见。在此,我们报告了一例在使用 177Lu-PSMA-617 后出现 2 级口干的不良事件通用术语标准版本 5 的病例。患者通过口腔卫生和口腔漱口水缓解口干症状。
{"title":"Management of Dry Mouth Toxicity Following <sup>177</sup>Lu-PSMA-617 Radioligand Therapy.","authors":"Abigail Pepin, Ana Kiess, J Nicholas Lukens, Philipose Mulugeta, Neil K Taunk","doi":"10.1016/j.prro.2024.10.014","DOIUrl":"10.1016/j.prro.2024.10.014","url":null,"abstract":"<p><p>Treatment options for patients with metastatic castration-resistant prostate cancer include the use of radioligand therapy with <sup>177</sup>Lu-PSMA-617. Although <sup>177</sup>Lu-PSMA-617 can selectively target prostate cancer cells, salivary glands express PSMA on the apical lumen of the acinar epithelium. Xerostomia resulting from the use of radioligand therapy is common. Herein, we report on a case of a Common Terminology Criteria for Adverse Events version 5 grade 2 dry mouth event after administration of <sup>177</sup>Lu-PSMA-617. The patient was managed with oral hygiene and xerostomia mitigation strategies using oral rinses.</p>","PeriodicalId":54245,"journal":{"name":"Practical Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142632442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiotherapy for Graves' Ophthalmopathy: When is the Optimal Timing of Treatment and Evaluation. 巴塞杜氏眼病的放射治疗:何时是治疗和评估的最佳时机?
IF 3.4 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-08 DOI: 10.1016/j.prro.2024.10.012
Ji Hyun Hong, Kyu Hye Choi, Ji Sang Kim, Suk Woo Yang, Yeon-Sil Kim

Purpose: Despite the decades of using radiotherapy for Graves' ophthalmopathy, the effects and optimal timing remain unclear. We retrospectively analyzed to evaluate the overall efficacy and response, predictive factors, and the effective timing of radiotherapy by assessing steroid requirement after radiotherapy in patients without prior surgery.

Methods and materials: Between 2008 and 2022, we analyzed 74 patients with Graves' ophthalmopathy who received radiotherapy to both orbits. Concurrent steroid therapy was administered to 51 patients. Symptoms were evaluated using a modified clinical activity score (CAS), defining responders as those with a two or more score improvement in CAS, diplopia, or a significant reduction in exophthalmos asymmetry. Common symptoms included eye swelling (81.1%), and conjunctival edema (81.1%). Diplopia observed in 48 patients (64.9%).

Results: Median follow-up was 44.5 months (range 4.8-169.6). CAS significantly improved in the early-immediate phase, one month after radiotherapy (p<0.001). However, diplopia showed significant improvement at a relatively late phase, 4 months after radiotherapy (p=0.039). Patients treated with steroids concurrently showed a faster response compared to those without steroids. Initiating radiotherapy within 12 months of symptom onset resulted in a shorter duration of steroid use after radiotherapy compared to later initiation (65 vs. 286 days, p=0.011).

Conclusions: Our study suggests an evaluation period of at least four months after radiotherapy regardless of concurrent steroid treatment, recognizing the prolonged improvement timeline for diplopia. Additionally, for reducing steroid use after radiotherapy, our study suggests optimal timing of radiotherapy within 12 months of symptom onset.

目的:尽管放疗治疗巴塞杜氏眼病已有几十年的历史,但其效果和最佳时机仍不明确。我们进行了回顾性分析,通过评估未接受过手术的患者放疗后对类固醇的需求,评估放疗的总体疗效和反应、预测因素以及有效时机:2008年至2022年间,我们分析了74例接受双眼眶放疗的巴塞杜氏眼病患者。51名患者同时接受了类固醇治疗。我们使用改良临床活动评分(CAS)对患者的症状进行了评估,并将CAS评分、复视或眼球外侧不对称程度显著降低且改善两分或两分以上者定义为应答者。常见症状包括眼睛肿胀(81.1%)和结膜水肿(81.1%)。48名患者(64.9%)出现复视:中位随访时间为 44.5 个月(4.8-169.6 个月)。CAS在放疗后一个月的早期明显改善(p结论:我们的研究表明,无论是否同时接受类固醇治疗,放疗后的评估期至少为四个月,因为复视的改善时间较长。此外,为了减少放疗后类固醇的使用,我们的研究建议放疗的最佳时间为症状出现后的 12 个月内。
{"title":"Radiotherapy for Graves' Ophthalmopathy: When is the Optimal Timing of Treatment and Evaluation.","authors":"Ji Hyun Hong, Kyu Hye Choi, Ji Sang Kim, Suk Woo Yang, Yeon-Sil Kim","doi":"10.1016/j.prro.2024.10.012","DOIUrl":"https://doi.org/10.1016/j.prro.2024.10.012","url":null,"abstract":"<p><strong>Purpose: </strong>Despite the decades of using radiotherapy for Graves' ophthalmopathy, the effects and optimal timing remain unclear. We retrospectively analyzed to evaluate the overall efficacy and response, predictive factors, and the effective timing of radiotherapy by assessing steroid requirement after radiotherapy in patients without prior surgery.</p><p><strong>Methods and materials: </strong>Between 2008 and 2022, we analyzed 74 patients with Graves' ophthalmopathy who received radiotherapy to both orbits. Concurrent steroid therapy was administered to 51 patients. Symptoms were evaluated using a modified clinical activity score (CAS), defining responders as those with a two or more score improvement in CAS, diplopia, or a significant reduction in exophthalmos asymmetry. Common symptoms included eye swelling (81.1%), and conjunctival edema (81.1%). Diplopia observed in 48 patients (64.9%).</p><p><strong>Results: </strong>Median follow-up was 44.5 months (range 4.8-169.6). CAS significantly improved in the early-immediate phase, one month after radiotherapy (p<0.001). However, diplopia showed significant improvement at a relatively late phase, 4 months after radiotherapy (p=0.039). Patients treated with steroids concurrently showed a faster response compared to those without steroids. Initiating radiotherapy within 12 months of symptom onset resulted in a shorter duration of steroid use after radiotherapy compared to later initiation (65 vs. 286 days, p=0.011).</p><p><strong>Conclusions: </strong>Our study suggests an evaluation period of at least four months after radiotherapy regardless of concurrent steroid treatment, recognizing the prolonged improvement timeline for diplopia. Additionally, for reducing steroid use after radiotherapy, our study suggests optimal timing of radiotherapy within 12 months of symptom onset.</p>","PeriodicalId":54245,"journal":{"name":"Practical Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142632542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Use of Magnetic Resonance Imaging for Postoperative Radiation Therapy Planning in Patients with Carbon Fiber-Reinforced Polyetheretherketone Instrumentation. 在使用 CFR-PEEK 器械的患者术后 RT 计划中使用 MRI。
IF 3.4 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-07 DOI: 10.1016/j.prro.2024.10.011
Jacob Ward, Mark Damante, Seth Wilson, Ahmed Nader Elguindy, Dominic Franceschelli, Vicente de Paulo Martins Coelho, Santino Cua, Daniel Kreatsoulas, Wesley Zoller, Sasha Beyer, Dukagjin Blakaj, Joshua Palmer, Raj Singh, Evan Thomas, Vikram Chakravarthy

Purpose: Carbon fiber-reinforced polyetheretherketone (CFR-PEEK) instrumentation is being used more frequently in the spinal oncology landscape. Better visualization with this material allows for more precise postoperative stereotactic body radiation therapy (SBRT) planning using either computed tomography (CT)-myelography or magnetic resonance imaging (MRI) studies. We compared the dosimetric planning equivalencies and outcomes.

Methods and materials: Thirty-six consecutively treated patients were reviewed who underwent spinal fusion using CFR-PEEK instrumentation for spine metastases followed by postoperative SBRT between January 1, 2022, and April 3, 2023. Patients were divided into 2 cohorts based on the imaging modality, MRI versus CT-myelogram, used for postoperative SBRT planning. Surgical, demographic, postoperative radiation dosimetry, complication, and survival data were collected. Statistical analysis was performed in SPSS (v29.0.1.0).

Results: Eleven patients underwent CT-myelograms, and 25 patients underwent MR-spine imaging for SBRT planning. The median follow-up was 145.5 days (13-530). There were no significant differences between baseline demographic, surgical characteristics, or SBRT dosimetry between the MRI spine and CT-myelogram groups. There was no significant difference between the cohorts for survival (P = .402).

Conclusions: MR scans are an effective choice for postoperative SBRT contouring patients using CFR-PEEK instrumentation for oncologic spinal fusions. Avoidance of CT-myelography reduces the need for an invasive procedure and potential risks including cerebrospinal fluid (CSF) leak, nerve root injury, and increased procedural burden.

背景和目的:碳纤维增强型 PEEK 器械在脊柱肿瘤领域的应用越来越广泛。使用这种材料可以获得更好的可视化效果,从而可以使用 CT 髓鞘造影术或核磁共振成像研究进行更精确的术后立体定向体放射治疗(SBRT)规划。我们比较了剂量规划的等效性和结果:方法:我们对 306 例连续接受治疗的患者进行了回顾性研究,这些患者在 2022 年 1 月 1 日至 2023 年 3 月 4 日期间使用 CFR-PEEK 器械对脊柱转移瘤进行了脊柱融合术,术后接受了 SBRT。根据术后 SBRT 计划使用的成像模式(MRI 与 CT-髓鞘造影),患者被分为两组。收集了手术、人口统计学、术后放射剂量测定、并发症和生存数据。统计分析在 SPSS(v29.0.1.0)中进行:11名患者接受了CT-髓鞘造影,25名患者接受了磁共振脊柱成像以进行SBRT计划。中位随访时间为 145.5 天 [13-530]。MRI脊柱成像组和CT髓鞘造影组在基线人口统计学、手术特征或SBRT剂量学方面没有明显差异。两组患者的生存率无明显差异(P=0.402):结论:磁共振扫描是使用CFR-PEEK器械进行肿瘤脊柱融合术的患者术后SBRT轮廓扫描的有效选择。结论:磁共振扫描是使用CFR-PEEK器械进行肿瘤性脊柱融合术的SBRT术后轮廓扫描患者的有效选择,避免了CT脊髓造影,减少了侵入性手术的需要和潜在风险,包括CSF渗漏、神经根损伤和增加的手术负担。
{"title":"Use of Magnetic Resonance Imaging for Postoperative Radiation Therapy Planning in Patients with Carbon Fiber-Reinforced Polyetheretherketone Instrumentation.","authors":"Jacob Ward, Mark Damante, Seth Wilson, Ahmed Nader Elguindy, Dominic Franceschelli, Vicente de Paulo Martins Coelho, Santino Cua, Daniel Kreatsoulas, Wesley Zoller, Sasha Beyer, Dukagjin Blakaj, Joshua Palmer, Raj Singh, Evan Thomas, Vikram Chakravarthy","doi":"10.1016/j.prro.2024.10.011","DOIUrl":"10.1016/j.prro.2024.10.011","url":null,"abstract":"<p><strong>Purpose: </strong>Carbon fiber-reinforced polyetheretherketone (CFR-PEEK) instrumentation is being used more frequently in the spinal oncology landscape. Better visualization with this material allows for more precise postoperative stereotactic body radiation therapy (SBRT) planning using either computed tomography (CT)-myelography or magnetic resonance imaging (MRI) studies. We compared the dosimetric planning equivalencies and outcomes.</p><p><strong>Methods and materials: </strong>Thirty-six consecutively treated patients were reviewed who underwent spinal fusion using CFR-PEEK instrumentation for spine metastases followed by postoperative SBRT between January 1, 2022, and April 3, 2023. Patients were divided into 2 cohorts based on the imaging modality, MRI versus CT-myelogram, used for postoperative SBRT planning. Surgical, demographic, postoperative radiation dosimetry, complication, and survival data were collected. Statistical analysis was performed in SPSS (v29.0.1.0).</p><p><strong>Results: </strong>Eleven patients underwent CT-myelograms, and 25 patients underwent MR-spine imaging for SBRT planning. The median follow-up was 145.5 days (13-530). There were no significant differences between baseline demographic, surgical characteristics, or SBRT dosimetry between the MRI spine and CT-myelogram groups. There was no significant difference between the cohorts for survival (P = .402).</p><p><strong>Conclusions: </strong>MR scans are an effective choice for postoperative SBRT contouring patients using CFR-PEEK instrumentation for oncologic spinal fusions. Avoidance of CT-myelography reduces the need for an invasive procedure and potential risks including cerebrospinal fluid (CSF) leak, nerve root injury, and increased procedural burden.</p>","PeriodicalId":54245,"journal":{"name":"Practical Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142632543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Appropriateness criteria for radiotherapy in the setting of presumed early-stage lung cancer. 推测早期肺癌放疗的适当性标准。
IF 3.4 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-06 DOI: 10.1016/j.prro.2024.10.010
Laura L Dover, Christopher Abraham, Adam J Kole, Ashley Weiner

Low-dose chest CT imaging for lung cancer screening is revealing increasing numbers of radiographic early-stage lung cancers. This topic discussion describes when a clinical scenario merits radiotherapy without a histologic diagnosis, with an emphasis on pragmatic algorithms in settings without readily-available advanced biopsy techniques.

用于肺癌筛查的低剂量胸部 CT 成像发现了越来越多的放射性早期肺癌。本专题讨论介绍了在没有组织学诊断的临床情况下何时需要进行放射治疗,重点是在没有现成先进活检技术的情况下的实用算法。
{"title":"Appropriateness criteria for radiotherapy in the setting of presumed early-stage lung cancer.","authors":"Laura L Dover, Christopher Abraham, Adam J Kole, Ashley Weiner","doi":"10.1016/j.prro.2024.10.010","DOIUrl":"https://doi.org/10.1016/j.prro.2024.10.010","url":null,"abstract":"<p><p>Low-dose chest CT imaging for lung cancer screening is revealing increasing numbers of radiographic early-stage lung cancers. This topic discussion describes when a clinical scenario merits radiotherapy without a histologic diagnosis, with an emphasis on pragmatic algorithms in settings without readily-available advanced biopsy techniques.</p>","PeriodicalId":54245,"journal":{"name":"Practical Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142632520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Practical Radiation Oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1